| Followers | 604 |
| Posts | 24107 |
| Boards Moderated | 3 |
| Alias Born | 12/06/2009 |
Tuesday, October 03, 2017 11:56:15 AM
$MYMX Shares are on LOCKDOWN! .071x.075
91 Mil Float Vaccine Stock
Totally undervalued!
91 Million Float/ 300 M. O/S
https://www.mymetics.com
(OTCQB: MYMX) is a Swiss based biotechnology company, with a Research Lab in the Netherlands. The company is registered in the US and trades on the OTCQB. Our delivery platform is being validated through partnership with leading pharmaceutical or research organisations, including Sanofi (NYSE:SNY), PATH-MVI and the Bill and Melinda Gates Foundation.
SANOFI PASTEUR will evaluate Mymetic's influenza virosomes in comparison to standard egg-based split vaccine
https://www.lawinsider.com/contracts/14FRg0Oj3httFR69PJYFLC/mymetics-corp/927761/2016-12-01
8K Filing of Agreement with Sanofi:
https://www.otcmarkets.com/edgar/GetFilingHtml?FilingID=11714959
"Item 1.01 Entry into a Material Definitive Agreement.
On November 28, 2016, the registrant, Mymetics Corporation, through its Dutch subsidiary, Mymetics BV ("Mymetics"), entered into a Research Agreement (the "Agreement"), effective October 21, 2016, with Sanofi Pasteur Biologics, LLC ("Sanofi"), the vaccine division of Sanofi SA. Sanofi will evaluate the immunogenicity of influenza vaccines based on Mymetics’ proprietary virosome technology platform in pre-clinical settings compared to egg-based split vaccines. Mymetics expects to enter into a more extensive collaboration with Sanofi should the evaluation by Sanofi be positive."
12. Term and Termination
12.1 This Agreement is made effective as of the Effective Date and shall expire one (1) year later unless extended for a certain period of time on the same terms and conditions by mutual written agreement of the Parties.
* Basically, Sanofi has entered into an agreement to evaluate MYMX's Vaccine Virosome technology!
* The Agreement Expires on October 21st, 2017!
* Virosomes are like "envelopes," that are a type of delivery system for vaccines using membranes, proteins, and antigens,... and MYMX has developed their own proprietary methods and has obtained many patents in the vaccine field that are related to their Virosome Technologies & Vaccine Pipeline.
*Sanofi Wants to compare Virosome based vaccines to the traditional egg-based vaccine, and evaluate a partnership, if Successful MYMX believes further collaboration will happen.
*Similar companies like MYMX in the past have been acquired for billions of dollars... for instance; Crucell (another vaccine company from the Netherlands) was acquired by Johnson and Johnson for 2.4 Billion Dollars.
*Sanofi, just recently bought a vaccine producer for 650 Million
91 Mil Float Vaccine Stock
Totally undervalued!
91 Million Float/ 300 M. O/S https://www.mymetics.com
(OTCQB: MYMX) is a Swiss based biotechnology company, with a Research Lab in the Netherlands. The company is registered in the US and trades on the OTCQB. Our delivery platform is being validated through partnership with leading pharmaceutical or research organisations, including Sanofi (NYSE:SNY), PATH-MVI and the Bill and Melinda Gates Foundation.
SANOFI PASTEUR will evaluate Mymetic's influenza virosomes in comparison to standard egg-based split vaccine
https://www.lawinsider.com/contracts/14FRg0Oj3httFR69PJYFLC/mymetics-corp/927761/2016-12-01
8K Filing of Agreement with Sanofi:
https://www.otcmarkets.com/edgar/GetFilingHtml?FilingID=11714959
"Item 1.01 Entry into a Material Definitive Agreement.
On November 28, 2016, the registrant, Mymetics Corporation, through its Dutch subsidiary, Mymetics BV ("Mymetics"), entered into a Research Agreement (the "Agreement"), effective October 21, 2016, with Sanofi Pasteur Biologics, LLC ("Sanofi"), the vaccine division of Sanofi SA. Sanofi will evaluate the immunogenicity of influenza vaccines based on Mymetics’ proprietary virosome technology platform in pre-clinical settings compared to egg-based split vaccines. Mymetics expects to enter into a more extensive collaboration with Sanofi should the evaluation by Sanofi be positive."
12. Term and Termination
12.1 This Agreement is made effective as of the Effective Date and shall expire one (1) year later unless extended for a certain period of time on the same terms and conditions by mutual written agreement of the Parties.
* Basically, Sanofi has entered into an agreement to evaluate MYMX's Vaccine Virosome technology!
* The Agreement Expires on October 21st, 2017!
* Virosomes are like "envelopes," that are a type of delivery system for vaccines using membranes, proteins, and antigens,... and MYMX has developed their own proprietary methods and has obtained many patents in the vaccine field that are related to their Virosome Technologies & Vaccine Pipeline.
*Sanofi Wants to compare Virosome based vaccines to the traditional egg-based vaccine, and evaluate a partnership, if Successful MYMX believes further collaboration will happen.
*Similar companies like MYMX in the past have been acquired for billions of dollars... for instance; Crucell (another vaccine company from the Netherlands) was acquired by Johnson and Johnson for 2.4 Billion Dollars.
*Sanofi, just recently bought a vaccine producer for 650 Million
Join the InvestorsHub Community
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
